{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:16:16Z","timestamp":1787163376537,"version":"build-2736575974"},"reference-count":18,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T00:00:00Z","timestamp":1300233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science"],"published-print":{"date-parts":[[2011,6,1]]},"abstract":"<jats:p>The World Health Assembly is scheduled to decide in May 2011 whether the 2 known remaining stockpiles of smallpox virus are to be destroyed or retained. In preparation for this, a WHO-appointed committee undertook a comprehensive review of the status of smallpox virus research from 1999 to 2010. It concluded that, considering the nature of the studies already completed with respect to vaccine, drugs, and diagnostics, there was no reason to retain live smallpox virus except to satisfy restrictive regulatory requirements. The committee advised that researchers and regulators define alternative models for testing the vaccines and drugs. Apart from other considerations, the costs of new products are significant and important. These include prospective expenditures required for the development, manufacture, testing, and storage of new products. This commentary provides approximations of these costs and the incremental contribution that a newly developed vaccine might make in terms of public health security.<\/jats:p>","DOI":"10.1089\/bsp.2011.0011","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T15:10:24Z","timestamp":1300288224000},"page":"163-168","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Smallpox Virus Destruction and the Implications of a New Vaccine"],"prefix":"10.1177","volume":"9","author":[{"given":"D. A.","family":"Henderson","sequence":"first","affiliation":[{"name":"Center for Biosecurity of UPMC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2011,3,16]]},"reference":[{"key":"e_1_3_1_2_2","unstructured":"World Health Organization. Report of the Meeting of the Ad Hoc Committee on Orthopoxvirus Infections. WHO Document no. WHO\/CDS\/BVI\/94.3: Geneva Switzerland September 9 1994."},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1126\/science.263.5143.13.b","article-title":"Smallpox virus stocks","volume":"263","author":"Baltimore D","year":"1994","unstructured":"Baltimore D. Smallpox virus stocks. Science, 1994; 263:13.","journal-title":"Science"},{"issue":"1","key":"e_1_3_1_4_2","doi-asserted-by":"crossref","DOI":"10.1089\/bsp.2010.0065","article-title":"Breaking the deadlock over destruction of the smallpox virus stocks","volume":"9","author":"Tucker JB","year":"2011","unstructured":"Tucker JB. Breaking the deadlock over destruction of the smallpox virus stocks. Biosecur Bioterror, 2011; 9,1epub ahead of print.","journal-title":"Biosecur Bioterror"},{"key":"e_1_3_1_5_2","volume-title":"Scientific review of variola virus research, 1999\u20132010","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. Scientific review of variola virus research, 1999\u20132010. Geneva: WHO, December 2010."},{"key":"e_1_3_1_6_2","volume-title":"WHO Document no. WHO\/HSE\/GAR\/BDP\/ 2010.4","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. Advisory Group of Independent Experts to review the smallpox research programme (AGIES): Comments on the Scientific Review of Variola Virus Research, 1999\u20132010. WHO Document no. WHO\/HSE\/GAR\/BDP\/ 2010.4. Geneva: WHO, December 2010."},{"key":"e_1_3_1_7_2","unstructured":"World Health Organization. WHO Advisory Committee on Variola Virus Research: Report of the Twelfth Meeting Geneva Switzerland 17\u201318 November 2010. WHO Document no. WHO\/HSE\/GAR\/BDP\/2010.5. Geneva: WHO 2010."},{"key":"e_1_3_1_8_2","unstructured":"World Health Organization. Report of the Meeting of the Ad Hoc Committee on Orthopoxvirus Infections. Geneva Switzerland 14 January 1999. WHO Document no. WHO\/CDS\/CSR\/99.1. Geneva: WHO 1999."},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2004.09.002"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.20965\/jdr.2009.p0329","article-title":"Research on preparedness for bioterorism\u2014associated events in Japan: smallpox vaccine preparedness","volume":"4","author":"Saito T","year":"2009","unstructured":"Saito T. Research on preparedness for bioterorism\u2014associated events in Japan: smallpox vaccine preparedness. Journal of Disaster Research, 2009; 4:329\u2013336.","journal-title":"Journal of Disaster Research"},{"issue":"5","key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"von Krempelhuber A","year":"2010","unstructured":"von Krempelhuber A, , Vollmar J, , Pokorny R et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine, 2010 Feb 3 28,5:1209\u20131216.","journal-title":"Vaccine"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/009286150403800301"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.22.2127"},{"key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/infdis\/122.4.303","article-title":"Complications of smallpox vaccination, 1968: results of ten statewide surveys","volume":"122","author":"Lane JM","year":"1970","unstructured":"Lane JM, , Ruben FL, , Neff JM, , Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis, 1970; 122:303\u2013309.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_15_2","unstructured":"Military Vaccine Agency and the Vaccine Healthcare Centers Network. Used with permission."},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01689-09"},{"issue":"12","key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3390\/v2122740","article-title":"Development of CMX001 for the treatment of poxvirus infections","volume":"2","author":"Lanier R","year":"2010","unstructured":"Lanier R, , Trost L, , Tippen T et al. Development of CMX001 for the treatment of poxvirus infections. Viruses, 2010; 2,12:2740\u20132762.","journal-title":"Viruses"},{"key":"e_1_3_1_18_2","unstructured":"IMVAMUNE. MVA-BN\u00ae based third-generation smallpox vaccine candidate. Bavarian-Nordic. http:\/\/www.bavarian-nordic.com\/pipeline\/imvamune-smallpox-vaccine.aspx. 2011 March 8."},{"issue":"10","key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S1473-3099(05)70242-5","article-title":"Smallpox vaccine and its stockpile in 2005","volume":"5","author":"Arita I","year":"2005","unstructured":"Arita I. Smallpox vaccine and its stockpile in 2005. Lancet Infect Dis, 2005 Oct 5,10:647\u2013652.","journal-title":"Lancet Infect Dis"}],"container-title":["Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/bsp.2011.0011","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/bsp.2011.0011","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/bsp.2011.0011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:40:59Z","timestamp":1777452059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/bsp.2011.0011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,16]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6,1]]}},"alternative-id":["10.1089\/bsp.2011.0011"],"URL":"https:\/\/doi.org\/10.1089\/bsp.2011.0011","relation":{},"ISSN":["1538-7135","1557-850X"],"issn-type":[{"value":"1538-7135","type":"print"},{"value":"1557-850X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,16]]}}}